← Sandoz overview

Sandoz vs Alvotech: why the prices moved differently

Weekly · monthly · quarterly news summaries, side by side in time

Sandoz Group AG (SDZ.SW)

Q3 2026
▲3▼1

Sandoz bets big on biosimilars as US tariff threat looms

  • US 100% generic tariff threat Trump threatened 100% tariffs on generic medicines, a direct risk to Sandoz's low-margin generics business. Its CEO warned tariffs would not bring production to the US and could disrupt supply of vital medicines, weighing on the shares.

    A major policy threat to Sandoz's core generics business and a real counterweight to the positive news.

  • Strong H1 results and raised margin guidance First-half sales rose 10% to $5.76bn, with biosimilars up 25% and now a third of sales. Profit margins expanded and full-year margin guidance was raised, showing the biosimilar bet is paying off and supporting the shares.

    Hard financial results that confirm the growth story and underpin the stock.

  • Bio100 strategy and pipeline expansion Sandoz unveiled Bio100, aiming to lead biosimilars by 2040 with over 100 products and to more than double sales in a decade. It added a Henlius partnership worth up to $322m and a $300m Slovenia plant, giving investors a long-term growth plan.

    The strategy and pipeline deals set the long-term direction that drives the investment case.

  • New market approvals and Thailand talks Brazil approved Sandoz's semaglutide diabetes drug Owozy for launch in a $1.8bn market, and Thailand plans a cooperation deal within weeks to draw Sandoz investment. Both widen its reach, though near-term financial impact is limited.

    Shows geographic expansion that adds future sales, a smaller but genuine positive driver.

August 2026
▲3▼1

Sandoz bets big on biosimilars as US tariff threat looms

  • US 100% generic tariff threat Trump threatened 100% tariffs on generic medicines, a direct risk to Sandoz's low-margin generics business. Its CEO warned tariffs would not bring production to the US and could disrupt supply of vital medicines, weighing on the shares.

    A major policy threat to Sandoz's core generics business and a real counterweight to the positive news.

  • Strong H1 results and raised margin guidance First-half sales rose 10% to $5.76bn, with biosimilars up 25% and now a third of sales. Profit margins expanded and full-year margin guidance was raised, showing the biosimilar bet is paying off and supporting the shares.

    Hard financial results that confirm the growth story and underpin the stock.

  • Bio100 strategy and pipeline expansion Sandoz unveiled Bio100, aiming to lead biosimilars by 2040 with over 100 products and to more than double sales in a decade. It added a Henlius partnership worth up to $322m and a $300m Slovenia plant, giving investors a long-term growth plan.

    The strategy and pipeline deals set the long-term direction that drives the investment case.

  • New market approvals and Thailand talks Brazil approved Sandoz's semaglutide diabetes drug Owozy for launch in a $1.8bn market, and Thailand plans a cooperation deal within weeks to draw Sandoz investment. Both widen its reach, though near-term financial impact is limited.

    Shows geographic expansion that adds future sales, a smaller but genuine positive driver.

Latest
▲3▼1

Sandoz bets big on biosimilars as US tariff threat looms

  • US 100% generic tariff threat Trump threatened 100% tariffs on generic medicines, a direct risk to Sandoz's low-margin generics business. Its CEO warned tariffs would not bring production to the US and could disrupt supply of vital medicines, weighing on the shares.

    A major policy threat to Sandoz's core generics business and a real counterweight to the positive news.

  • Strong H1 results and raised margin guidance First-half sales rose 10% to $5.76bn, with biosimilars up 25% and now a third of sales. Profit margins expanded and full-year margin guidance was raised, showing the biosimilar bet is paying off and supporting the shares.

    Hard financial results that confirm the growth story and underpin the stock.

  • Bio100 strategy and pipeline expansion Sandoz unveiled Bio100, aiming to lead biosimilars by 2040 with over 100 products and to more than double sales in a decade. It added a Henlius partnership worth up to $322m and a $300m Slovenia plant, giving investors a long-term growth plan.

    The strategy and pipeline deals set the long-term direction that drives the investment case.

  • New market approvals and Thailand talks Brazil approved Sandoz's semaglutide diabetes drug Owozy for launch in a $1.8bn market, and Thailand plans a cooperation deal within weeks to draw Sandoz investment. Both widen its reach, though near-term financial impact is limited.

    Shows geographic expansion that adds future sales, a smaller but genuine positive driver.

Alvotech (ALVO)

Q3 2026
▲2▼1

Alvotech's FDA Wins and Lotus Deal Offset Heavy Dilution

  • Dilution from $125M equity raise Alvotech sold new shares to raise about $125 million, which means each existing share now represents a smaller slice of the company. That dilutes current holders and is a direct drag on the stock price, even though the cash funds biosimilar development and launches.

    This is the first major event of the period and a clear negative price driver.

  • $240M total capital raised, but costly debt Alvotech added a $75 million term loan to the $165 million equity raise, giving it $240 million in fresh capital for its pipeline and global expansion. The loan carries a high 12.5% interest rate, so it strengthens the balance sheet but adds real leverage risk that could weigh on future profits.

    This is the period's key financing update and explains both the cash cushion and the added risk.

  • FDA clears Reykjavik plant, unlocking biosimilar approvals The FDA closed its inspection of Alvotech's Iceland factory with a clean 'Voluntary Action Indicated' status, meaning problems were fixed. This removes a regulatory cloud and supports pending U.S. applications for several biosimilars, making future approvals and sales more likely.

    This is a new regulatory milestone that directly lifts the stock and de-risks the pipeline.

  • Lotus deal and AVT80 FDA acceptance expand market reach Alvotech signed a licensing deal with Lotus for two biosimilars worth up to $150 million plus supply revenue, and the FDA accepted its application for AVT80, a subcutaneous Entyvio biosimilar. Both broaden access to oncology, hematology and gut-disease markets, though near-term revenue still depends on approval timing.

    These are the period's main growth catalysts, adding new revenue streams and pipeline progress.

July 2026
▲2▼1

Alvotech's FDA Wins and Lotus Deal Offset Heavy Dilution

  • Dilution from $125M equity raise Alvotech sold new shares to raise about $125 million, which means each existing share now represents a smaller slice of the company. That dilutes current holders and is a direct drag on the stock price, even though the cash funds biosimilar development and launches.

    This is the first major event of the period and a clear negative price driver.

  • $240M total capital raised, but costly debt Alvotech added a $75 million term loan to the $165 million equity raise, giving it $240 million in fresh capital for its pipeline and global expansion. The loan carries a high 12.5% interest rate, so it strengthens the balance sheet but adds real leverage risk that could weigh on future profits.

    This is the period's key financing update and explains both the cash cushion and the added risk.

  • FDA clears Reykjavik plant, unlocking biosimilar approvals The FDA closed its inspection of Alvotech's Iceland factory with a clean 'Voluntary Action Indicated' status, meaning problems were fixed. This removes a regulatory cloud and supports pending U.S. applications for several biosimilars, making future approvals and sales more likely.

    This is a new regulatory milestone that directly lifts the stock and de-risks the pipeline.

  • Lotus deal and AVT80 FDA acceptance expand market reach Alvotech signed a licensing deal with Lotus for two biosimilars worth up to $150 million plus supply revenue, and the FDA accepted its application for AVT80, a subcutaneous Entyvio biosimilar. Both broaden access to oncology, hematology and gut-disease markets, though near-term revenue still depends on approval timing.

    These are the period's main growth catalysts, adding new revenue streams and pipeline progress.

Latest
▲2▼1

Alvotech's FDA Wins and Lotus Deal Offset Heavy Dilution

  • Dilution from $125M equity raise Alvotech sold new shares to raise about $125 million, which means each existing share now represents a smaller slice of the company. That dilutes current holders and is a direct drag on the stock price, even though the cash funds biosimilar development and launches.

    This is the first major event of the period and a clear negative price driver.

  • $240M total capital raised, but costly debt Alvotech added a $75 million term loan to the $165 million equity raise, giving it $240 million in fresh capital for its pipeline and global expansion. The loan carries a high 12.5% interest rate, so it strengthens the balance sheet but adds real leverage risk that could weigh on future profits.

    This is the period's key financing update and explains both the cash cushion and the added risk.

  • FDA clears Reykjavik plant, unlocking biosimilar approvals The FDA closed its inspection of Alvotech's Iceland factory with a clean 'Voluntary Action Indicated' status, meaning problems were fixed. This removes a regulatory cloud and supports pending U.S. applications for several biosimilars, making future approvals and sales more likely.

    This is a new regulatory milestone that directly lifts the stock and de-risks the pipeline.

  • Lotus deal and AVT80 FDA acceptance expand market reach Alvotech signed a licensing deal with Lotus for two biosimilars worth up to $150 million plus supply revenue, and the FDA accepted its application for AVT80, a subcutaneous Entyvio biosimilar. Both broaden access to oncology, hematology and gut-disease markets, though near-term revenue still depends on approval timing.

    These are the period's main growth catalysts, adding new revenue streams and pipeline progress.

© 2026 MarketDXWhy